Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

Benzinga Newsdesk www.benzinga.com Neutral 76.8%

Neg 0% Neu 76.8% Pos 0%

Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.